PRODUCT PIPELINE


Blue Earth Diagnostics’ commitment is to develop and commercialise innovative radiopharmaceutical agents that have the potential to inform management decisions or treat patients with serious disease, such as cancer. These agents are designed to have a positive impact on patient care, with a focus on areas of significant unmet medical need. Here you can explore details of our research pipeline, arranged by product.


Product/Candidate
DISEASE/THERAPEUTIC AREA
Application
Preclinical
Phase 1
Phase 2
Phase 3

fluciclovine(18F)

Brain metastases

PET imaging

FAP-targeted technology

Multiple solid tumours 

PET imaging

Abbreviations:
PET = Positron Emission Tomography
FAP = Fibroblast Activation Protein

 

Our sister company, Blue Earth Therapeutics, continues to investigate the use of rhPSMA-10.1 as a therapeutic agent. For more information see

https://www.blueearththerapeutics.com/pipeline

 

PP-UK-0618 / May 2023